The major factors that are expected to be driving the high content screening market are need for cost containment in pharma R&D, growth in funding for cellular research, and technological advancements in HCS solutions are expected to support the growth of the HCS market during the forecast period

What the Market Looks Like?

[343 Pages Report] The anatomic pathology market is projected to reach USD 49.1 billion by 2026 from USD 35.1 billion in 2021, at a CAGR of 7.0%. The global anatomic pathology market is segmented into North America, Europe, the Asia Pacific, and the Rest of the World (RoW). 

COVID -19 Impact on Anatomic Pathology Market

Globally, the COVID-19 outbreak has impacted every aspect of the diagnostics industry, including the anatomic pathology market. In the last few months, the number of patient visits to hospitals has reduced significantly, despite emergency and OPD services being available in hospitals.

Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=137323145

The growth of the anatomic pathology market is majorly driven by the high incidence of cancer and other target diseases, recommendations for cancer screening, availability of reimbursement, and the growing focus on personalized medicine. In addition, emerging economies such as China, India, and Brazil are expected to offer significant growth opportunities for players operating in the anatomic pathology market during the forecast period.

What are Key Trends in the Market?

The growth of the Anatomic Pathology Market is primarily influenced by the following factors:

• High incidence of cancer and other target diseases
• Recommendations for cancer screening
• Availability of reimbursement
• Growing focus on personalized medicine
•  Increasing number of clinical trials pertaining to cancer drugs
• Emerging markets offer lucrative opportunities

Based on application, the anatomic pathology market is segmented into disease diagnostics and medical research. The disease diagnostics segment accounted for a larger share of the market in 2020 due to the rapid growth in the geriatric population and the increasing incidence of cancer and other chronic diseases.

Read more about Anatomic Pathology Market
@ https://www.marketsandmarkets.com/requestsampleNew.asp?id=137323145

The growth in this market is majorly driven by the high incidence of cancer and other target diseases, availability of reimbursement, and the growing focus on personalized medicine. However, the availability of refurbished products, the lack of skilled professionals, and product recalls are expected to hamper the market growth to a certain extent during the forecast period.

[306 Pages Report] The global anatomic pathology market size is estimated to grow from USD 33.3 billion in 2020 to USD 46.8 billion by 2025, at a CAGR of 7.1%.

Market Dynamics

• High incidence of cancer and other target diseases
• Recommendations for cancer screening
• Availability of reimbursement
• Growing focus on personalized medicine

COVID-19 Impact on Anatomic Pathology Market

Globally, the COVID-19 outbreak has impacted every aspect of the diagnostics industry, including the anatomic pathology market. In the last few months, the number of patient visits to hospitals has reduced significantly, despite emergency and OPD services being available in hospitals.

Download PDF Brochure @   https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=137323145 

By product & service, the anatomic pathology market is segmented into services, instruments, and consumables. The services segment accounted for the largest market share in 2019 and is expected to register the highest CAGR during the forecast period. The growth of this segment can be attributed to the availability of reimbursements for diagnostic tests, rapid growth in the geriatric population, and the increasing incidence of cancer and other chronic diseases.

The geographical regions mapped in the report are:

• North America
• Europe
• Asia Pacific
• Rest of the World
• Latin America
• Middle East & Africa

Based on the region, the global anatomic pathology market is segmented into North America, Europe, the Asia Pacific, and the Rest of the World. In 2019, North America accounted for the largest market share, followed by Europe. The easy accessibility to advanced technologies, government initiatives for screening cancer patients, favorable reimbursement scenario for anatomic pathology diagnostic tests, increasing healthcare expenditure, and the presence of high-quality infrastructure for hospitals and clinical laboratories in the region are the major factors driving the growth of the anatomic pathology market in North America.

Request for sample pages @   https://www.marketsandmarkets.com/Market-Reports/anatomic-pathology-market-137323145.html 

Some key players mentioned in the research report are:

Prominent players in the anatomic pathology market include F. Hoffmann-La Roche Ltd. (Switzerland), Danaher Corporation (US), Hologic, Inc. (US), Agilent Technologies (US), Becton, Dickinson and Company (US), PHP Holdings Corporation (Japan), Sakura Finetek (Japan), Merck KGaA (Germany), Bio SB (US), Diapath S.p.A. (OTCPK:ITALY), and BioGenex Laboratories (US).

According to the new market research report “Anatomic Pathology Market by Product & Service (Instruments (Tissue Processing Systems, Microtomes), Consumables (Antibodies), Histopathology), Application (Disease Diagnosis (Cancer (Gastrointestinal)), End User (Hospital, Lab) – Global Forecast to 2024″, , published by MarketsandMarkets™, The anatomic pathology market is estimated to grow from USD 33.0 billion in 2019 to USD 44.4 billion by 2024, at a CAGR of 6.1%.

However, the availability of refurbished products, the lack of skilled professionals, and product recalls are expected to hamper market growth to a certain extent during the forecast period

Anatomic Pathology Market by Product & Service (Instruments (Tissue Processing Systems, Microtomes), Consumables (Antibodies), Histopathology), Application (Disease Diagnosis (Cancer (Gastrointestinal)), End User (Hospital, Lab) – Global Forecast to 2024

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=137323145

The Anatomic Pathology Market is Segmented on:

1. Product & Service
2. Consumables
3. Application
4. End User

Services segment to witness the highest growth during the forecast period

By product & service, the market is segmented into services, instruments, and consumables. The services segment accounted for the largest market share in 2018 and is expected to register the highest CAGR during the forecast period.

Disease diagnosis segment accounted for the largest share of the anatomic pathology market, by application, in 2018

Based on application, the market is segmented into disease diagnosis and medical research. The market for disease diagnosis is further segmented into cancer and other diseases. In 2018, the disease diagnosis segment accounted for the largest market share.

Get a sample PDF copy of the Report @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=137323145

The geographical regions mapped in the report are:

•  North America
• Europe
• Asia Pacific
• Rest of the World

North America is the largest regional market for anatomic pathology

In 2018, North America accounted for the largest market share, followed by Europe. The easy accessibility to advanced technologies, government initiatives for screening cancer patients, favorable reimbursement scenario for anatomic pathology diagnostic tests, increasing healthcare expenditure, and the presence of high-quality infrastructure for hospitals and clinical laboratories in the region are the major factors driving the growth of the market in North America.

Some key players mentioned in the research report are:

Prominent players in anatomic pathology market are F. Hoffmann-La Roche Ltd. (Switzerland), Danaher Corporation (US), Thermo Fisher Scientific (US), Hologic, Inc. (US), Agilent Technologies (US), Becton, Dickinson and Company (US), Sakura Finetek (Japan), Merck KGaA (Germany), Bio SB (US), Diapath S.p.A. (Italy), and BioGenex Laboratories (US).